ArticleFrontiers in nutrition2026
Structural characterization and effect on diabetes mellitus with ulcerative colitis of polysaccharide from
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Shiliang tea, derived from the leaves of Methods: The structural features of CSP were determined using gel permeation chromatography, gas chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy. Following oral administration of CSP, colonic tissues from diabetic mice were collected for histological examination. Concentrations of short‑chain fatty acids (SCFAs) in colonic contents were measured by gas chromatography. Results: A polysaccharide (CSP) with an approximate molecular mass of 574.7 kDa was isolated from Chimonanthus salicifolius. Methylation analysis revealed that CSP comprises ten distinct sugar residues, while NMR spectra showed the presence of terminal α-arabinofuranosyl (T-α-Araf), 1,5- and 1,3,5-linked α-Araf, terminal β-galactopyranosyl (T-β-Galp), 1,3,6-, 1,4,6-, 1,4-, and 1,3-substituted β-Galp, as well as 1,4- and 1,3-linked α-glucopyranosyl (α-Glcp) residues in CSP. CSP administration markedly attenuated hyperglycemia and impeded the progression of ulcerative colitis in diabetic mice. CSP significantly suppressed pro inflammatory cytokine production, predominantly via blockade of NF‑κB signaling cascade. CSP reinforced intestinal epithelial barrier function through upregulation of tight junction associated proteins, including claudin 1, occludin, and zonula occludens 1, and concurrently elevated the concentrations of SCFAs within the colonic lumen. Conclusion: These results indicate that CSP is a bioactive polysaccharide with demonstrable biological activity in animal models, warranting further investigation as a potential therapeutic agent for diabetic colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.